Delivery Order SPE2DR25D7068-SPE2DR26F5BU7
- Not listed
- The Defense Logistics Agency awarded a $6,644.52 delivery order to AmerisourceBergen Drug Corp on December 3, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens with a completion date of December 4, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used in diabetes and weight management therapy, reflecting the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $1,284.26 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pens on April 21, 2025, with completion expected by April 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used in diabetes and weight management treatment, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 ml pens with a ceiling value of $2,726.72. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and represents a non-set-aside competitive award. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,741.51 to AmerisourceBergen Drug Corp on November 24, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. This non-competitive, firm fixed-price delivery order is scheduled for completion by November 25, 2025, with performance taking place at the contractor's corporate headquarters in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, reflecting the Defense Logistics...
- The Defense Logistics Agency awarded a delivery order valued at $1,908.64 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pens on September 4, 2025, with completion scheduled for September 5, 2025. This firm fixed-price delivery order, which carries no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management and represents part of the Defense Logistics Agency's...
- The Defense Logistics Agency awarded a delivery order valued at $7,000.21 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pens on December 3, 2025, with an ultimate completion date of December 4, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,963.10 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on August 7, 2025, with completion expected by August 8, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management and represents part of the...
- The Defense Logistics Agency awarded a delivery order valued at $42,562.60 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on July 30, 2025, with completion targeted for July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, reflecting the federal government's...
- The Defense Logistics Agency awarded a delivery order valued at $10,065.66 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on August 29, 2025. This firm fixed price delivery order is non-set-aside and will be fulfilled from the vendor's place of performance in Conshohocken, Pennsylvania, with a completion date of September 2, 2025. Zepbound is a GLP-1 receptor agonist medication used for weight management, reflecting the Defense Logistics Agency Medical Supply...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $28,197.83 for Zepbound 10 mg/0.5 mL pens on July 17, 2025, with completion scheduled for July 18, 2025. This firm fixed-price, competitively awarded delivery order was issued without set-aside designation and will be performed at the contractor's corporate headquarters in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management, reflecting the Defense Logistics Agency's...
- SPE2DR25D7068Indefinite Delivery Contract
- SPE2DR25D7068-SPE2DR26F5BU7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,074.20 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on December 4, 2025, with a completion date of December 5, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used in weight management, reflecting the Defense Logistics Agency Medical Supply Chain's ongoing procurement of pharmaceutical products to support military and federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen Drug Corp maintains an extensive portfolio of delivery orders across multiple therapeutic domains, including diabetes medications, neurological treatments, and specialized medical supplies. The company's demonstrated capability to fulfill competitive federal procurement requirements positions it as a key supplier supporting the Defense Health Agency and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.1k | 12/3/25 |